Vol 43, No 4 (2012)
Untitled
Published online: 2012-10-01

open access

Page views 200
Article views/downloads 253
Get Citation

Connect on Social Media

Connect on Social Media

The current opinion on the place of plerixafor in hematopoietic stem cell mobilization

Grzegorz Władysław Basak, Kazimierz Hałaburda1, Wiesław Wiktor Jędrzejczak1
DOI: 10.1016/S0001-5814(12)70002-6
Acta Haematol Pol 2012;43(4):317-325.

Abstract

Plerixafor is a specific antagonist of the CXCR4 chemokine receptor used for mobilization of hematopoietic stem cells from bone marrow to peripheral blood for their collection and subsequent transplantation. The European label indications include patients with lymphoma and multiple myeloma whose cells mobilise poorly. Because of its high efficacy when used in combination with G-CSF, it has been used mainly in patients with failed previous mobilization (“failed mobilizers”). However, label indications include plerixafor usage also in patients predicted to mobilize poorly (“predicted poor mobilizers”) as well as those with suboptimal current mobilization (“proven poor mobilizers”). Also patients who mobilize efficiently (“good mobilizers”) might benefit from mobilization with plerixafor. The paper demonstrates the use of plerixafor in above situations. Also a “rescue” strategy of plerixafor use during stem cell mobilization is presented.

Article available in PDF format

View PDF (Polish) Download PDF file